Meta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

被引:2
|
作者
Elzanaty, Ahmed M. [1 ]
Nazir, Salik [2 ]
Awad, Mohammed T. [1 ]
Elsheikh, Eman [3 ]
Ahuja, Keerat Rai [4 ]
Donato, Anthony [5 ]
Eltahawy, Ehab A. [2 ]
机构
[1] Univ Toledo, Med Ctr, Dept Internal Med, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Med Ctr, Dept Cardiol, 2801 W Bancroft St, Toledo, OH 43606 USA
[3] Tama Univ Hosp, Dept Cardiol, Tanta, Egypt
[4] Cleveland Clin, Dept Cardiol, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Tower Hlth Reading Hosp, W Reading, PA USA
关键词
Dual antiplatelet therapy; Short DAPT; P2Y(12) inhibitor monotherapy; DAPT duration; ELUTING STENT IMPLANTATION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; ASPIRIN; TRIAL; RISK; CLOPIDOGREL; TICAGRELOR; 6-MONTH; EVENTS;
D O I
10.1016/j.carrev.2020.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for >= 12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated. Objectives: We aimed to perform a meta-analysis of randomized controlled trials (RCT) comparing P2Y(12) mono-therapy in short-duration group (SDG) vs. standard treatment group (STG) course of DAPT in patients undergoing PCI. Methods: Electronic databases were searched for RCTs of patients undergoing percutaneous coronary intervention (PCI) with DES placement who received short (<= 3 months) vs. standard DAPT course (>= 12 months) and were followed for >= 12-months. Rates ofmajor adverse cardiovascular events (a composite of cardiovascularmortality, non-fatal myocardial infarction, and non-fatal stroke) were the primary outcome. Study-specific odds ratios (OR) and corresponding 95% confidence intervals were calculated using random-effects model. Results: A total of 20,706 patients (10,344 in the SDG and 10,362 in the STG) were analysed from four studies. There was no significant difference observed forMACE (OR= 0.95, 95% CI: 0.81-1.08, P =.92, I-2= 0%) myocardial infarction or stent thrombosis. However, lower rates ofmajor bleedingwere noted in the SDG (1.20 vs. 1.80%; OR: 0.61; 95% CI: 0.37-0.99; P =.04; I-2 = 71%) albeit with increased heterogeneity. Conclusion: A short duration of DAPT followed by P2Y(12) inhibitormonotherapy was comparable to 12 months of DAPT with respect to MACE and thrombotic events, with lower rates of major bleeding events in select group of patients undergoing PCI. More data is needed to assess efficacy in patients with complex lesions and high risk ACS population including those with STEMI presentation. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [1] P2Y12 INHIBITOR MONOTHERAPY AFTER A SHORT DUAL ANTIPLATELET THERAPY VS. 12-MONTH DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
    Ling, Hua
    Egolum, Ugochukwu
    Parker, Shanea
    Ho, Ai-Chen
    Dimmel, Jordan
    Hawkins, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 73 - 73
  • [2] P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
    Ho, Ai-Chen
    Egolum, Ugochukwu
    Parker, Shanea
    Dimmel, Jordan
    Hawkins, Andrew
    Ling, Hua
    CLINICAL DRUG INVESTIGATION, 2020, 40 (09) : 799 - 808
  • [3] P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
    Ai-Chen Ho
    Ugochukwu Egolum
    Shanea Parker
    Jordan Dimmel
    Andrew Hawkins
    Hua Ling
    Clinical Drug Investigation, 2020, 40 : 799 - 808
  • [4] Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneous coronary intervention: meta-analysis of randomised controlled trials
    Roule, Vincent
    Lemaitre, Adrien
    Pommier, Wilhelm
    Bignon, Mathieu
    Sabatier, Remi
    Blanchart, Katrien
    Beygui, Farzin
    AGE AND AGEING, 2021, 50 (04) : 1102 - 1107
  • [5] Meta-analysis of Dual Antiplatelet Therapy Versus Monotherapy With P2Y12 Inhibitors in Patients After Percutaneous Coronary Intervention
    Malik, Aaqib H.
    Yandrapalli, Srikanth
    Shetty, Suchith S.
    Aronow, Wilbert S.
    Cooper, Howard A.
    Panza, Julio A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 127 : 25 - 29
  • [6] P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION
    Pil-Sang, Song
    Jin-Ok, Jeong
    JOURNAL OF HYPERTENSION, 2023, 41 : E178 - E178
  • [7] P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials
    Jin, Yao
    Huang, Hui
    Shu, Xinyi
    Chen, Shuai
    Lu, Lin
    Gao, Xiang
    Wu, Zhijun
    THROMBOSIS RESEARCH, 2021, 198 : 115 - 121
  • [8] Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention
    Feng, Wen-Han
    Chang, Yong-Chieh
    Lin, Yi-Hsiung
    Chen, Hsiao-Ling
    Chang, Hsiu-Mei
    Chu, Chih-Sheng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (09)
  • [9] P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
    McCaw, Zachary R.
    Wei, Lee-Jen
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (16): : 1607 - 1607
  • [10] P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
    Feng, Wen-Han
    Chang, Yong-Chieh
    Lin, Yi-Hsiung
    Chen, Hsiao-Ling
    Chen, Chun-Yin
    Lin, Tsung-Han
    Lin, Tzu-Chieh
    Chang, Ching-Tang
    Kuo, Hsuan-Fu
    Chang, Hsiu-Mei
    Chu, Chih-Sheng
    PHARMACEUTICALS, 2023, 16 (02)